Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc. announced the effectiveness of its 1-for-4 reverse stock split on November 3, 2026. This action, approved by the Board of Directors and stockholders, reduced the number of outstanding common shares from approximately 4.47 million to 1.12 million. The par value and voting rights remain unchanged. Fractional shares were settled with cash payments, and adjustments were made to outstanding equity awards and warrants.

Bluejay Diagnostics reported its second quarter 2026 financial results, ending the period with approximately $9.6 million in cash and cash equivalents, up from $5.2 million at year-end 2025. The company strengthened its financial position through $7.7 million in net cash from financing activities, including a $7.6 million private placement in June 2026, which is expected to fund operations through Q2 2027. Operationally, Bluejay completed targeted enrollment of 750 patients in its SYMON-II pivotal clinical study for the Symphony™ IL-6 test and signed a US manufacturing contract, advancing towards planned FDA 510(k) submission and commercialization.

Bluejay Diagnostics announced the completion of targeted patient enrollment for its SYMON-II pivotal clinical study, a key step towards FDA 510(k) submission for its Symphony IL-6 test. The company also reported a strong financial position, ending the second quarter of 2026 with approximately $9.6 million in cash and cash equivalents, following significant financing activities. This financial strength is expected to fund operations through the second quarter of 2027, supporting regulatory and commercialization efforts.

Bluejay Diagnostics reported a Q2 2026 net loss of $(2.32) million, an increase from $(1.96) million in Q2 2025. Despite the increased loss, the company's cash and cash equivalents significantly rose to $9.6 million as of June 30, 2026, primarily due to approximately $8.5 million in gross proceeds from a June 2026 private placement. Bluejay also announced the successful completion of patient enrollment for its SYMON-II clinical validation study for the Symphony IL-6 test, targeting an FDA 510(k) submission in the first half of 2027, but noted substantial doubt about its ability to continue as a going concern without further capital.

Bluejay Diagnostics, Inc. announced the successful completion of patient enrollment in its SYMON-II multicenter clinical validation study. The study enrolled 750 patients, achieving its target ahead of schedule, to evaluate the Symphony™ IL-6 test for assessing 28-day all-cause mortality risk in sepsis patients. This milestone provides a robust clinical dataset, with a preliminary 17% 28-day mortality rate observed, which is critical for the company's planned regulatory submissions and commercialization strategy.

Bluejay Diagnostics announced the successful and early completion of patient enrollment for its SYMON-II multicenter clinical validation study. The study enrolled 750 patients to evaluate the Symphony™ IL-6 test's ability to assess 28-day all-cause mortality risk in sepsis patients. This milestone provides a robust clinical dataset, with a preliminary 17% 28-day mortality rate, which is crucial for future regulatory submissions and commercialization efforts. The company expects to complete data analysis and reporting in the coming months.

Bluejay Diagnostics, Inc. held its 2026 annual meeting, where stockholders approved several key proposals. These included the re-election of five directors and the ratification of Wolf & Company, P.C. as the independent auditor. Significantly, stockholders approved an amendment to the 2021 Stock Plan, increasing the shares reserved for issuance by 600,000 to a total of 600,061. Additionally, a proposal for a reverse stock split, with a ratio between 1-for-2 and 1-for-20, was approved, granting the Board discretion to implement it within the next year to maintain Nasdaq compliance, though there is no present intention to do so.

Bluejay Diagnostics, Inc. announced the closing of a private placement of its securities, raising approximately $7.7 million in net proceeds after fees and expenses. The offering included pre-funded warrants, Series G warrants, and Series H warrants, with a combined price of $2.324 per unit. H.C. Wainwright & Co. served as the exclusive placement agent. The company intends to use the net proceeds to fund matters related to obtaining FDA approval, including clinical studies, as well as for other research and development activities and general working capital needs. Bluejay has also agreed to file a resale registration statement for the securities issued in the placement.

Bluejay Diagnostics, Inc. announced the closing of a private placement, securing $8.5 million in upfront gross proceeds. The offering involved the sale of 3,655,917 shares of common stock (or pre-funded warrants) and accompanying series G and H warrants, which could generate an additional $15.2 million if fully exercised. The company anticipates these net proceeds will extend its cash runway into the first quarter of 2027, beyond its expected FDA submission, and potentially well beyond FDA approval and first year of commercialization if warrants are fully exercised. The funds will be allocated towards obtaining FDA approval, related clinical studies, other research and development activities, and general working capital needs.

Bluejay Diagnostics, Inc. announced it has entered into definitive agreements for a private placement, expecting to raise $8.5 million in gross proceeds upfront. The offering includes 3,655,917 shares of common stock (or pre-funded warrants) and accompanying Series G and H warrants, with a purchase price of $2.325 per share. The company could receive an additional $15.1 million if the warrants are fully exercised. These funds are projected to extend Bluejay's cash runway into the first quarter of 2027, beyond its expected FDA submission, and will be used for FDA approval processes, research and development, and general working capital.